James F Watson
CIK 1420406 · last filed 2018-01-29
James F Watson is a corporate insider who has filed 3 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for MNLO, was dated Jan 29, 2018. Across all open-market trades the lifetime net is −$66.3M, making them a net seller over the disclosed history. 17 SEC filings were submitted jointly with David J Collier.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
655 MONTGOMERY STREET, SUITE 6-161
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. (MNLO) Delisted | 10%+ Owner | 2,267,799 | — | — | $0 | 1 | 2018-01-29 |
| INTERMOLECULAR INC (IMI) Delisted | 10%+ Owner | 0 | — | — | -$59.15M | 1 | 2014-11-12 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | 10%+ Owner | 100,362 | — | — | -$7.14M | 1 | 2013-09-20 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-29 | VYNE Therapeutics Inc. (MNLO) Delisted | Conv (C) | +6,028,590 | $0 | EDGAR |
| 2014-11-12 | INTERMOLECULAR INC (IMI) Delisted | Sell (S) | −26,887,530 | -$59.15M | EDGAR |
| 2013-09-20 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −700,000 | -$7.14M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.